论文部分内容阅读
作者对85名18～24月龄的健康儿童分别接种Connaught药厂和Praxis药厂生产的b型流感杆菌(Hib)多糖菌苗,比较评价了两种菌苗的安全性及免疫原性。接种菌苗的儿童均采用双盲法,随机按年龄分组。42名17～19月龄儿童中,23人接种Praxis菌苗(菌苗A),19人接种Connaught菌苗(菌苗B)。43名24～26月龄儿童中,21人接种菌苗A,22人接种菌苗B。作者记录了种苗后6、24和48小时的肛温、全身反应以及局部反应。在接种菌苗前及接种后4、6周采取血液标本,用放射免疫法测定抗荚膜抗体。冻干菌苗接种剂量为25μg/0.5ml。
The author of 85 healthy children aged 18 to 24 months were vaccinated Connaught Pharmaceutical Factory and Praxis pharmaceutical production of b-type influenza bacilli (Hib) polysaccharide vaccine, compared the safety evaluation of the two vaccines and immunogenicity. Children vaccinated with vaccines are double-blind, randomly grouped by age. Of 42 children aged 17-19 months, 23 were vaccinated with Praxis (Vaccine A) and 19 were challenged with Connaught (Vaccine B). Of the 43 children aged 24 to 26 months, 21 were inoculated with vaccine A and 22 were inoculated with vaccine B. The authors recorded rectal temperature, systemic reactions, and local reactions at 6, 24, and 48 hours after seedling emergence. Blood samples were taken before vaccination and at 4 and 6 weeks after inoculation, and anti-capsular antibodies were determined by radioimmunoassay. Lyophilized vaccine vaccination dose of 25μg / 0.5ml.